SEC Filing Summary: Medasorb Technologies Corporation (8-K)
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Medasorb Technologies Corporation (not Cytosorbents Corp) on January 19, 2007, covering events occurring on January 16, 2007. The company is incorporated in Nevada with its principal executive office in Monmouth Junction, New Jersey.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a specific corporate governance event regarding executive compensation.
Material Changes
On January 16, 2007, the Board of Directors approved a stock option grant to David Lamadrid, the Chief Financial Officer. The grant details are as follows:
- Total Shares: 150,000 shares of common stock.
- Exercise Price: $1.90 per share (closing price on the grant date).
- Vesting Schedule:
- 50,000 shares exercisable immediately.
- 50,000 shares exercisable on January 16, 2008.
- 50,000 shares exercisable on January 16, 2009.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management outlook, specific risks, contingencies, or unusual items beyond the standard disclosure of the option grant.
Investor Verification Checklist
- Verify the total number of outstanding shares to assess the dilution impact of the 150,000 new options.
- Confirm the current market price of the stock relative to the $1.90 exercise price.
- Review the company's most recent 10-K or 10-Q for financial performance data not included in this 8-K.
- Check for any subsequent filings regarding the vesting or exercise of these options.